Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 18/20 | 0.46 |
| ▸ | CTSD | P07339 | 5/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961366 | 1.00 | BACE1 (0.46) | BACE1CTSDAPPCTSB | |
| SCHEMBL12245060 | 1.00 | BACE1 (0.46) | BACE1CTSDAPPCTSB | |
| SCHEMBL12247363 | 0.95 | BACE1 (0.42) | BACE1CTSDAPP | |
| SCHEMBL7963717 | 0.94 | BACE1 (0.53) | BACE1CTSDAPPCTSB | |
| SCHEMBL12245071 | 0.94 | BACE1 (0.53) | BACE1CTSDAPPCTSB | |
| SCHEMBL7956156 | 0.94 | BACE1 (0.53) | BACE1CTSDAPPCTSB | |
| SCHEMBL7966375 | 0.93 | BACE1 (0.48) | BACE1CTSDAPP | |
| SCHEMBL7947756 | 0.93 | BACE1 (0.48) | BACE1CTSDAPP | |
| SCHEMBL7961973 | 0.93 | BACE1 (0.48) | BACE1CTSDAPP | |
| SCHEMBL7967110 | 0.93 | BACE1 (0.51) | BACE1CTSDAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | BACE1 1/4885CTSD 43/4885APP 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.